Report Categories
View AllRecent Articles
View All
Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement
How Scinai SCNI cash flow tells the real story Edges Lower 20260508
PNFPA Pinnacle fixedtofloating preferred stock posts steady quarterly performance amid interest rate volatility
LNAI Lunai Bioworks reports Q1 2026 EPS of negative 008 shares slip 081 percent with no analyst earnings estimates